Phase 2 N=139 COVID-19 Anosmia Study
Anosmia · Covid19
Primary: Change in Brief Smell Identification Test (BSIT) — 6.77; 7.20; 7.89; 7.88 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=51 Smell in Covid-19 and Efficacy of Nasal Theophylline
Covid19 · Anosmia · Olfactory Disorder
Primary: UPSIT — 59; 43 percentage of participants
N/A N=30 Acupuncture Therapy for COVID-Related Olfactory Loss
Olfactory Dysfunction · COVID-19
Primary: Change in University of Pennsylvania Smell Identification Test (UPSIT) Scores — 2.571; 3.182 score on a scale
N/A N=51 Steroid Nasal Irrigation for Flavor Evaluation and Detection Study
Olfactory Disorder
Primary: Pre- and Post-intervention Difference in Functional Connectivity Before and After Smell Training. — 5 Regions of interest
Phase 4 N=121 Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Alzheimer Disease · Mild Cognitive Impairment · Delirium, Dementia, Amnestic, Cognitive Disorders
Primary: Change Over Time in Selective Reminding Test (SRT) Scores — 36.14; 21.19; 39.99; 24.10 Words
N/A N=50 Evaluation of Smell and Taste in Fibromyalgia
Fibromyalgia
Primary: Sniffin' Sticks Test Score — 25.96; 36.40 score on a scale
Phase 4 N=41 Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil
Mild Cognitive Impairment
Primary: Selective Reminding Test (SRT) — 33.61; 36.23; 36.81; 37.13 Words
Phase 2 N=27 Smell Changes & Efficacy of Nasal Theophylline
Olfactory Disorder · Anosmia · Viral Infection
Primary: Number of Patients With Improvement in Global Rating of Smell Change — 4; 3 Participants
N/A N=1,320 Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects
COVID-19
Primary: Sensitivity, Specificity and Accuracy — 889; 106; 27; 20 Participants
N/A N=100 Smell Sensitivity in Chronic Migraine: A Case-Control Study
Chronic Migraine · Olfactory Acuity
Primary: Comparison of UPSIT Scores Between Subjects and Controls at Two Time Points — 34.5; 35.9; 34.7; 36.1 UPSIT Score
Phase 2 N=48 Stellate Ganglion Block for COVID-induced Parosmia
COVID-19-Induced Parosmia
Primary: Parosmia Olfactory Dysfunction Outcomes Rating — 9; 9; 14; 11 score on a scale 0-112
Phase 2 N=77 Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3)
COVID-19
Primary: Clinical Global Impression - Improvement Scale — 9; 9 Participants
Phase 2 N=68 Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction
COVID-19 · Olfactory Disorder · Anosmia
Primary: Clinical Global Impression of Improvement Scale (CGI-I) — 8; 20; 7; 12 Participants
Phase 2 N=15 Directed Topical Drug Delivery for Treatment for PASC Hyposmia
Post Acute Sequelae Covid-19 Hyposmia
Primary: Percentage of Participants Achieving MCID (Minimal Clinically Important Difference) on the Smell Identification Test (SIT) — 66.70; 28.57; 66.70; 42.86 percentage of…
Phase 2 N=20 Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
Anosmia · Hyposmia · Parosmia
Primary: Clinical Global Impression - Improvement (CGI-I) Score — 12; 8; 0; 0 Participants
Phase 2 N=7 Helping Olfaction and Nutrition On Renal Replacement
End Stage Renal Disease · Olfactory Disorders
Primary: Change From Baseline in Smell Identification Test Score at 6 Weeks — 4 units on a scale
Phase 4 N=102 Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis
Allergic Rhinitis
Primary: Product Preference Questionnaire for Immediate Taste — 26.47; 10.78; 5.88; 15.69 Percentage of participants
N/A N=9 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
N/A N=50 Posterior Nasal Nerve (PNN) Rhinitis Study
Chronic Rhinitis
Primary: Change in Reflective Total Nasal Symptom Score (rTNSS) — -5.1 units on a scale — p=<0.0001
Phase 3 N=240 The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)
Amnestic Mild Cognitive Impairment · Alzheimer's Disease
Primary: Change in Global Measure of Cognition as Measured by the Alzheimer's Disease Assessment Scale-Cognitive 12 (ADAS-Cog12) — 3.893; 3.867; 7.091; 6.164 Modeled change score…
Phase 3 N=223 12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device
Nasal Polyps
Primary: Adverse Events — 169 Participants
Phase 2 N=40 SB705498 Proof of Concept Chamber Challenge in Subjects With Non Allergic Rhinitis
Rhinitis
Primary: Mean Total Symptom Score (TSS) Elicited by a 1 Hour (h) Cold Dry Air (CDA) Challenge, 1 h and 24 h on Day 14 to Compare the Effect of 14 Day Repeat Dosing of Intranasal…